( PARIS--(BUSINESS WIRE)--May 31 2007 - ...)Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference,Health

PARIS--(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development and manufacture of new drug entities for pandemic disease threats, announced today a new scientific report featuring its antiviral therapeutic product candidate Alferon-LDO in combating highly pathogenic avian influenza (HPAI), also known as "bird flu." Alferon-LDO is a low-dose experimental oral formulation of the Company's Alferon-N(TM) product, which is already approved by the United States FDA for the treatment of refractory genital warts (HPV).

The report concludes that Alferon-LDO appears to have potential as a preventive agent and/or treatment against avian influenza, reducing the severity of pathology resulting from infection of established animal model non-human primates (macaques) by a highly pathogenic strain of avian flu.

As noted in a 2006 Oxford University Clinical Research Unit study titled "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia," illness caused by the avian influenza A virus stems most directly from the body's own response to infection, an overwhelming reaction sometimes termed a "cytokine storm." In the words of the Oxford University study, "high viral load, and the resulting intense inflammatory responses, are central to influenza H5N1 pathogenesis. The focus of clinical management should be on preventing this intense cytokine response, by early diagnosis and effective antiviral treatment."

To study the effects of Alferon-LDO, researchers administered macaque subjects with the drug via the animals' gum tissues, in a range of three dosing concentrations, with a fourth untreated group serving as a control. Following exposure of the dosed and untreated test subjects to the highly pathogenic HPAI strain A/Vietnam/1194/04, throat and nasal swabs were taken, gross pathology and viral lo
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein